Understanding Semaglutide: The Original Weekly GLP-1 Semaglutide (Ozempic for type 2 diabetes, Wegovy for weight management) was the first GLP-1 receptor agonist built for once-weekly dosing
Glycogen metabolism in humans
On August 8, Novo Nordisk announced preliminary results of its phase 3 SELECT trial, which launched in 2018
Although the idea of gentle, fractional dosing sounds appealing, microdosing can limit effectiveness, delay results, and create inconsistent responses
Rybelsus maxes out at 14 mg for type 2 diabetes That dose gap translates directly to results: ~16.6% body weight reduction with Wegovy pill vs
Clothes may fit better, movement may feel easier, and patients often feel encouraged to support their health in other ways